News
-
September 21, 2017- Provention to initiate Phase 2a Study of PRV-6527 (JNJ-40346527) in patients with moderate to severe Crohn's disease
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
July 18, 2017- Enterovirus vaccine platform in-licensed from Vactech Oy will be developed to "pre-empt" type 1 diabetes by targeting coxsackievirus B infection
Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
July 11, 2017Accomplished Biopharmaceutical and Drug Development Executive to Spearhead Provention's Vision of Intercepting and Preventing Immune-mediated Disease
Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...
-
June 26, 2017Industry innovators, Francisco Leon, MD, Ph.D. and Ashleigh Palmer, cofound newly established company
Provention Bio, Inc., a recently founded clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...